Premium
Analysis of 2013 European LeukaemiaNet ( ELN ) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
Author(s) -
Jain Preetesh,
Kantarjian Hagop,
Sasaki Koji,
Jabbour Elias,
Dasarathula Jyothsna,
Nogueras Gonzalez Graciela,
Verstovsek Srdan,
Borthakur Gautam,
Wierda William,
Kadia Tapan,
Dellasala Sara,
Pierce Sherry,
Ravandi Farhad,
O'Brien Susan,
Cortes Jorge
Publication year - 2016
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13936
Subject(s) - nilotinib , medicine , dasatinib , imatinib , imatinib mesylate , tyrosine kinase inhibitor , tyrosine kinase , oncology , myeloid leukemia , cancer , receptor
Summary This study assessed the relevance of 2013 European LeukaemiaNet ( ELN ) response categories on patients treated with common frontline tyrosine kinase inhibitors ( TKI ) in chronic myeloid leukaemia in chronic phase ( CML ‐ CP ). Four hundred and eighty‐seven patients treated with imatinib (400 mg; IM 400, n = 70; 800 mg; IM 800, n = 201), dasatinib ( n = 107) or nilotinib ( n = 109) were analysed. Intention to treat ( ITT ) analysis indicated that the proportion of patients falling into optimal, warning and failure ELN categories were 89%, 6%, 6% at 3 months, 78%, 17% and 6% at 6 months, and 75%, 13% and 13% at 12 months, respectively. Rates of optimal response at 3 months were 75% for IM 400, 90% for IM 800, 89% for dasatinib and 97% for nilotinib; 41%, 80%, 86% and 89% at 6 months; and 47%, 77%, 76% and 87% at 12 months, respectively. Patients achieving optimal response had longer eventfree ( EFS ), failurefree ( FFS ), transformationfree ( TFS ) and overall survival ( OS ) compared to warning and failure responses at all‐time points. Treatment with imatinib 800, dasatinib or nilotinib predicted for achieving an optimal response. Optimal response predicted for significantly longer EFS , FFS , TFS and OS at 3, 6 and 12 months, irrespective of the TKI modality used. ELN response categories reliably predicted outcomes in CML patients receiving commonly used TKI s.